Who is sponsoring NCT04256616?

NCT04256616 is sponsored by Istituto Clinico Humanitas.

What condition does NCT04256616 study?

NCT04256616 studies Bladder Cancer.

Is NCT04256616 still recruiting?

NCT04256616 is currently status unknown. Last updated 7 July 2020.

Last reviewed 2020-07-07 · How we verify

NCT04256616: ICH-MIM-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer

Status unknown Last updated 7 July 2020

What this trial tests

trial testing This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients. in Bladder Cancer in 110 participants. Status unknown.

Timeline

27 June 2018

Primary endpoint
1 September 2020

30 September 2020

Quick facts

Lead sponsor	Istituto Clinico Humanitas
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	110
Start date	27 June 2018
Primary completion	1 September 2020
Estimated completion	30 September 2020
Sites	1 location across Italy

Drugs / interventions tested

This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

Istituto Clinico Humanitas

Who can join

40 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal objective of this study consists in the assessment of Immunogenic Cell Death (ICD) induction in neoplastic tissues derived from bladder cancer patients treated ex vivo with Mitomycin C (MMC). The evaluation is performed using cellular and molecular analyses of treated versus untreated samples derived from the same patient

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment.
Fabian KP, Wolfson B, Hodge JW. · · 2021 · cited 77× · PMID 34497771 · DOI 10.3389/fonc.2021.728018
Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.
Wang J, Ma J, Xie F, Miao F, et al · · 2024 · cited 19× · PMID 38745666 · DOI 10.3389/fimmu.2024.1389173
The war between the immune system and the tumor - using immune biomarkers as tracers.
Yang K, Lu R, Mei J, Cao K, et al · · 2024 · cited 9× · PMID 38816871 · DOI 10.1186/s40364-024-00599-5
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers.
Pfail J, Drobner J, Doppalapudi K, Saraiya B, et al · · 2024 · cited 6× · PMID 38846356 · DOI 10.33696/cancerimmunol.6.078
Mitochondrion: Main organelle in orchestrating cancer escape from chemotherapy.
Mostafavi S, Eskandari N. · · 2024 · cited 4× · PMID 38151790 · DOI 10.1002/cnr2.1942

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Istituto Clinico Humanitas trials

Trials by the same sponsor.

NCT06944288 — Microbiota as Early Diagnostic and predictivE Factor for Osteoarthritic Degeneration and Microbial Contamination · NA · not yet recruiting
NCT07358247 — Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction · not yet recruiting
NCT07362342 — RIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery · not yet recruiting
NCT07346274 — Intra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. · enrolling by invitation
NCT07491419 — The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04256616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituto Clinico Humanitas
Last refreshed: 7 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04256616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing